Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Invitae | RCV000641057 | SCV000762675 | pathogenic | Carney-Stratakis syndrome; Pheochromocytoma; Paragangliomas 1; Cowden syndrome 3 | 2018-10-31 | criteria provided, single submitter | clinical testing | This variant is a gross deletion of the genomic region encompassing exon 4 of the SDHD gene. The 5' boundary is likely confined to intron 3. The 3' end of this event is unknown as it extends through the termination codon beyond the assayed region for this gene and may encompass additional genes. While this deletion is not anticipated to result in nonsense mediated decay, it is expected to create a truncated protein product or disrupt mRNA translation. Similar deletions of exon 4 have been reported in at least 5 families affected with paragangliomas, with many of the individuals presenting with single or multiple head and neck paragangliomas. Amongst the families, these variants were shown to segregate with disease in 20 of the affected individuals (PMID: 19454582, 20111059, 22382802). In one of the studies, the deletion of exon 4 was suggested to be an Austrian founder mutation (PMID: 20111059). A founder mutation (p.Leu139Pro) has been reported in the deleted region (PMID: 21348866, 11391798), and a different truncation that occurs within the deleted region (p.Gln109*) has been determined to be pathogenic (PMID: 11897817, 19454582, 25720320). This suggests that deletion of this region of the SDHD protein is causative of disease. For these reasons, this variant has been classified as Pathogenic. |